TOP > 外国特許検索 > AGENT FOR KILLING HIV-1-INFECTED CELL AND APPLICATION THEREOF

AGENT FOR KILLING HIV-1-INFECTED CELL AND APPLICATION THEREOF UPDATE

外国特許コード F160008850
整理番号 (S2015-0401-N0)
掲載日 2016年9月23日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP051768
国際公開番号 WO 2016117666
国際出願日 平成28年1月22日(2016.1.22)
国際公開日 平成28年7月28日(2016.7.28)
優先権データ
  • 20150-011506 JP
  • 特願2015-119111 (2015.6.12) JP
発明の名称 (英語) AGENT FOR KILLING HIV-1-INFECTED CELL AND APPLICATION THEREOF UPDATE
発明の概要(英語) The present invention pertains to: an agent for killing HIV-1-infected cells, the agent containing a compound shown by formula (I): (in the formula, Ar1 and Ar2 are the same or different, and are optionally substituted aromatic groups; X is -CH2O- or -CH=CH-), a salt thereof, or a solvate of these; and a combination formulation for simultaneous, separate, or sequential administration in the treatment or prevention of HIV-1 infection, wherein the combination formulation contains two separate formulations: (a) a formulation including a compound shown by formula (I), a salt thereof, or a solvate of these, and (b) a formulation including an anti-HIV-1 drug.
従来技術、競合技術の概要(英語) BACKGROUND ART
2013 All over the world in the year individuals infected HIV-1 million people have about 3,500, about 210 million new HIV-1 infected persons and as high as, the infection may be HIV-1, still, worldwide major public health problem.
However, the present anti-HIV-1 agents, growth can be inhibited HIV-1 is, infected HIV-1 infected cells in the patient body cannot be eliminated more effectively. Therefore, the lifetime of the infected persons HIV-1 HIV-1 anti-over must be taking drugs, anti-HIV-1 to long-term ingestion by chronic toxicity of the drug in the drug-resistance HIV-1 problem due to the appearance. Therefore, the current, of the complete HIV-1 infection therapy development is increasingly required. In addition, about 40 year treatment period when the provisional, individuals infected with HIV-1 medical care cost is about 1 million yen per person and such social medical care cost is expensive and causes a significant problem, the development of HIV-1 radical therapy has been desired from around the world.
A complete cure of the infection HIV-1 are difficult HIV-1 is caused mainly by the presence of a cell in latent infection. Latent infection cells, resting memory CD4 mainly long lifetime+ THIV-1 cells and infected cells, the cells are in the genomic DNA in HIV-1 present as proviral DNA, growth-stimulating a cell such as an activation stimulus in the absence of HIV-1 particles most HIV-1 proteins are not produced, activated upon stimulation HIV-1 production starts. Most of the drugs the present anti-HIV-1 HIV-1 since enzymes derived from a target, the production can be suppressed HIV-1 is, latent infection HIV-1 is not possible to reduce the number of cells. Therefore, the establishment of a therapy to cure HIV-1, latent infection HIV-1 is used as a target in the development of therapeutic cells is required.
Is suppressed so that the function of histone deacetylase, highly acetylated histones by causing (histone deacetylase, HDAC) gene affects the expression of histone deacetylase inhibitors, tumor suppressor gene or cancer by changing the expression of the, anti-tumor effect. Already, some HDAC inhibitors, as methods of treatment for solid and hematologic tumors, alone or as a combination therapy, in the early stage of clinical development.
On the other hand, hepatocellular carcinoma and hepatitis C, such as H. pylori infection and gastric cancer, chronic infection and there is a correlation in rats is known. This includes, activation of inflammatory signaling system such as the induction of expression of various genes, as cancer and chronic inflammation has a common molecular mechanism is believed to be involved.
Recently, entinostat, vorinostat several HIV-1 HDAC latent infection of the cell inhibitor is activated (reservoir cells), can induce the production of HIV-1 has been reported (non-patent document 1).
Patent Document 1 and 2, as well as the non-patent document 2, entinostat HDAC inhibitor, such as benzamide derivatives chidamido (chidamide) malignant tumors, autoimmune diseases, skin diseases, for the treatment of parasitic infection, to be useful as an ameliorating agent is described.
Heretofore, entinostat HIV-1 infected human mononuclear cells by specific cell death induction for there are no reports of the effects.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • OKAMOTO MIKA
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close